Signaling Pathways in Disease
Signaling Pathways in Disease is a research topic within Molecular Biology. Science Explorer counts 24k research works in it since 1950. 21.0% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the role of Calcineurin-NFAT signaling in transcriptional regulation, with a particular emphasis on its involvement in cancer progression, cardiac hypertrophy, and inflammatory responses. The cluster also explores the impact of Prolyl Isomerase Pin1, EMMPRIN/CD147, and immunophilins in modulating this signaling pathway.
- Calcineurin
- NFAT
- Transcriptional Regulation
- Prolyl Isomerase Pin1
- Cancer Progression
- Cardiac Hypertrophy
- Immunophilins
- EMMPRIN/CD147
- Peptidyl-Prolyl Isomerases
- Inflammatory Responses
- Research works
- 24k fractional, since 1950
- In the world top 10%
- 4.9k per year above
- Top-10% rate
- 21.0% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- -9% the tick is no change
Which countries lead Signaling Pathways in Disease research?
By volume, China and the United States publish the most (924 and 518 works in 2022–2025).
By volume, 2022–2025
- 1 China 924 works
- 2 United States 518 works
- 3 Germany 126 works
- 4 Japan 98 works
- 5 India 91 works
- 6 United Kingdom 75 works
- 7 South Korea 64 works
- 8 Italy 59 works
- 9 France 50 works
- 10 Canada 46 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Signaling Pathways in Disease research?
By volume in 2022–2025, Sun Yat-sen University publishes the most Signaling Pathways in Disease research, followed by Chinese Academy of Medical Sciences & Peking Union Medical College and Nanjing Medical University.
By volume, 2022–2025
- 1 Sun Yat-sen UniversityChina 13 works
- 2 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 13 works
- 3 Nanjing Medical UniversityChina 12 works
- 4 Shanghai Jiao Tong UniversityChina 12 works
- 5 Huazhong University of Science and TechnologyChina 11 works
- 6 Nantong UniversityChina 10 works
- 7 Fujian Medical UniversityChina 9 works
- 8 Wuhan UniversityChina 9 works
- 9 Sichuan UniversityChina 9 works
- 10 University of North Carolina at Chapel HillUnited States 9 works
Who are the leading researchers in Signaling Pathways in Disease?
The most-cited researchers publishing on Signaling Pathways in Disease include Zena Werb and Peter R. Galle.
- 1 Zena Werb United States 3.3k citations
- 2 Peter R. Galle Germany 3.3k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Signaling Pathways in Disease research done?
The largest centres of Signaling Pathways in Disease research in 2022–2025 are Beijing (China), Shanghai (China), Guangzhou (China) and Nanjing (China).
Where is the best place to study Signaling Pathways in Disease?
Among universities, judged by research, Huazhong University of Science and Technology, Nanjing Medical University and Chinese Academy of Medical Sciences & Peking Union Medical College score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Huazhong University of Science and TechnologyChina | 63.7 | 33.4% | 2.8× | 11 | +69.1% |
| 2 | Nanjing Medical UniversityChina | 63.4 | 14.3% | 9.6× | 12 | +80.0% |
| 3 | Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina | 62.0 | 24.9% | 5.5× | 13 | +16.2% |
| 4 | Nantong UniversityChina | 58.0 | 24.2% | 12.0× | 10 | -5.8% |
| 5 | Sun Yat-sen UniversityChina | 57.8 | 20.4% | 3.3× | 13 | +53.2% |
| 6 | Shanghai Jiao Tong UniversityChina | 57.3 | 24.8% | 2.2× | 12 | +64.7% |
| 7 | Southern Medical UniversityChina | 51.6 | 25.1% | 9.3× | 8 | +11.2% |
| 8 | Wuhan UniversityChina | 46.8 | 32.1% | 2.9× | 9 | +16.4% |
| 9 | Zhejiang UniversityChina | 45.6 | 30.2% | 1.7× | 8 | +36.7% |
| 10 | Sichuan UniversityChina | 39.0 | 30.3% | 2.1× | 9 | +12.6% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Signaling Pathways in Disease research growing?
Output in 2018–2022 was 9% lower than in 2013–2017, peaking in 2014. The fastest-growing topics are Signaling Pathways in Disease.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.